BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23404615)

  • 1. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results.
    Silverman S; Miller P; Sebba A; Weitz M; Wan X; Alam J; Masica D; Taylor KA; Ruff VA; Krohn K
    Osteoporos Int; 2013 Aug; 24(8):2309-17. PubMed ID: 23404615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.
    Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K
    Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study.
    Wong M; Wan X; Ruff V; Krohn K; Taylor K
    Osteoporos Int; 2012 Apr; 23(4):1445-52. PubMed ID: 21769662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
    Reginster JY; Kaufman JM; Goemaere S; Devogelaer JP; Benhamou CL; Felsenberg D; Diaz-Curiel M; Brandi ML; Badurski J; Wark J; Balogh A; Bruyère O; Roux C
    Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
    Ebina K; Hashimoto J; Shi K; Kashii M; Hirao M; Yoshikawa H
    Osteoporos Int; 2014 Dec; 25(12):2755-65. PubMed ID: 25082556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
    Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
    Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide.
    Boytsov N; Zhang X; Sugihara T; Taylor K; Swindle R
    Curr Med Res Opin; 2015; 31(9):1665-75. PubMed ID: 26121328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.
    Oswald AJ; Berg J; Milne G; Ralston SH
    Calcif Tissue Int; 2014 Feb; 94(2):176-82. PubMed ID: 24026567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
    Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
    Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
    Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
    Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Effects of Teriparatide Followed by Antiresorptive Therapy on Clinical Outcomes in Patients with Severe Spinal Osteoporosis.
    Oswald AJ; Berg K; Ralston SH; Riches PL
    Calcif Tissue Int; 2019 Aug; 105(2):148-155. PubMed ID: 31115640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.
    Nishikawa A; Yoshiki F; Taketsuna M; Kajimoto K; Enomoto H
    Clin Interv Aging; 2016; 11():1653-1659. PubMed ID: 27895472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.